Thiazolidinediones

THIAZOLES with two keto oxygens. Members are insulin-sensitizing agents which overcome INSULIN RESISTANCE by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma).

Also Known As:

Networked: 2250 relevant articles (181 outcomes, 271 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Staels, Bart: 14 articles (12/2021 - 08/2003)
2.	Scheen, A J: 14 articles (11/2008 - 03/2000)
3.	Singh, Sonal: 10 articles (12/2014 - 08/2007)
4.	Plutzky, Jorge: 9 articles (09/2008 - 01/2002)
5.	Fonseca, Vivian: 8 articles (01/2019 - 01/2003)
6.	Dandona, Paresh: 8 articles (03/2012 - 12/2003)
7.	Colca, Jerry R: 7 articles (01/2022 - 02/2004)
8.	Ferrannini, Ele: 7 articles (08/2012 - 03/2006)
9.	Hsueh, Willa A: 7 articles (01/2012 - 12/2003)
10.	Lasaridis, Anastasios N: 7 articles (12/2011 - 09/2004)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 09/01/2009 - "The thiazolidinediones are equally effective in improving glycaemic control when used in combination regimens in patients with type 2 diabetes, but have differing effects on the diabetic dyslipidaemia. " 12/01/2013 - "Given the promising results, this study concludes that the coadministration of spirulina does not influence the pharmacokinetics of glitazones in a type 2 diabetes rat model. " 06/01/2002 - "The glitazones: a new treatment for type 2 diabetes mellitus." 06/01/2007 - "Clinicians should become familiar with glitazones as they are experiencing a burgeoning use among patients with non-insulin-dependent diabetes mellitus and have demonstrated clinical efficacy in treating certain skin conditions." 01/01/2021 - "We studied 215 patients with type 2 diabetes participating in the Thiazolidinediones Or Sulphonylureas and Cardiovascular Accidents Intervention Trial study. "
2.	Insulin Resistance 06/01/1995 - "Agents that reduce insulin resistance include the thiazolidinediones, which are very effective in animals. " 07/01/2007 - "Both pharmacological intervention (i.e., thiazolidinediones [TZDs]) and lifestyle modification (i.e., exercise training) are clinically effective treatments for improving whole-body insulin sensitivity. " 12/01/1996 - "Clinical studies in patients with type II diabetes, as well as other syndromes characterized by insulin resistance, have demonstrated that thiazolidinediones may represent a safe and effective new treatment. " 02/25/2016 - "Thiazolidinediones are considered a promising treatment for HALS, because they improve insulin sensitivity and increase subcutaneous fat mass. " 09/01/2001 - "The thiazolidinediones are a new class of drug that ameliorate insulin resistance, and we await to see if their use is associated with improved diabetes outcomes. "
3.	Weight Gain 11/01/2018 - "Thiazolidinediones improved metabolic (2 of 5 reviews) and endocrine outcomes (one of 5 reviews) but worsened weight gain (5 of 5 reviews). " 03/01/2011 - "Other authors reported that thiazolidinediones give an improvement in the glycemic without giving weight gain. " 12/01/2013 - "Here, using in-depth physiology studies, we investigate whether obese patients with T2DM are likely to benefit from thiazolidinediones, medications with a known adverse effect of weight gain. " 09/01/2007 - "The larger trials have shown that glitazones produce a weight gain of 4-5 kg over 3-4 years of treatment, and the weight gain cannot be explained by fluid retention. " 07/01/2015 - "Established therapeutic classes, such as sulphonylureas and thiazolidinediones, have some properties undesirable in individuals with T2DM, such as hypoglycaemia risk, weight gain and fluid retention, highlighting the need for newer agents with more favourable safety profiles that can be combined and used at all stages of T2DM. "
4.	Weight Loss (Weight Reduction) 10/09/2023 - "This implies that treatments targeting Adipo-IR, such as weight loss strategies and certain medications, such as thiazolidinediones, might be particularly effective for these groups of women. " 12/01/2008 - "The weight of data point to greatest biochemical and histological benefit with weight-loss measures and thiazolidinediones, but further trials are needed to characterize the benefits and risks of the latter agents. " 04/01/2014 - "All patient subgroups had a mean weight loss irrespective of OAD continuation, apart from those continuing thiazolidinediones (+0·2 kg). " 01/01/2003 - "Is weight loss possible in patients treated with thiazolidinediones? " 01/01/2003 - "We conclude that a program of caloric restriction and behavior modification is effective in leading to weight loss in patients treated with thiazolidinediones. "
5.	Non-alcoholic Fatty Liver Disease 01/01/2021 - "The results of this study indicated that ZYC might be able to help T2DM patients with NAFLD to control the progress of NAFLD as an alternation of thiazolidinediones, synthetic agonists of PPARγ, whose side effects and adverse events should not be ignored." 10/01/2016 - "The findings regarding the effects of thiazolidinediones (TZDs) in nonalcoholic steatohepatitis (NASH) patients have been inconsistent, and the assessment of different clinical variables for evaluating the effects of TZDs confound a direct comparison of the results of different randomized clinical trials (RCTs), especially with regard to lifestyle changes. " 10/01/2016 - "Thiazolidinediones for nonalcoholic steatohepatitis: A meta-analysis of randomized clinical trials." 02/01/2010 - "Short-term trials of glitazones in nonalcoholic steatohepatitis (NASH) yielded controversial histological results. " 01/18/2006 - "In the treatment of nonalcoholic fatty liver disease, thiazolidinediones show considerable promise, but further clinical studies are required in order to prove their efficacity and safety."

Related Drugs and Biologics

1.	Metformin (Glucophage)
2.	Insulin (Novolin)
3.	Glucose (Dextrose)
4.	PPAR gamma
5.	Hypoglycemic Agents (Hypoglycemics)
6.	Peroxisome Proliferator-Activated Receptors (PPAR)
7.	Pioglitazone (Actos)
8.	Ligands
9.	Rosiglitazone (Avandia)
10.	Fibric Acids (Fibrates)

Related Therapies and Procedures

1.	Glycemic Control
2.	Therapeutics
3.	Stents
4.	Caloric Restriction
5.	Bariatric Surgery